Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Unicycive Therapeutics, Inc. securities, alleging misleading statements regarding the company's compliance with FDA manufacturing requirements and the regulatory prospects of its New Drug Application [1][5]. Group 1: Lawsuit Details - The class action lawsuit is filed for securities purchased between March 29, 2024, and June 27, 2025 [1]. - Investors who purchased Unicycive securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - The lawsuit claims that Unicycive's readiness to meet FDA manufacturing compliance was overstated, along with the regulatory prospects of its oxylanthanum carbunate New Drug Application [5]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must file a motion with the court by October 14, 2025, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions for investors [4].

Core Viewpoint - A class action securities lawsuit has been filed against Unicycive Therapeutics, Inc. due to alleged securities fraud affecting investors between March 29, 2024, and June 27, 2025 [1][2]. Company Summary - The lawsuit claims that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements and the regulatory prospects of its oxylanthanum carbonate new drug application, leading to materially false and misleading public statements [2]. - Investors who suffered losses during the specified timeframe have until October 14, 2025, to request appointment as lead plaintiff, with no costs or obligations to participate in the class action [3]. Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on behalf of shareholders who purchased securities during the specified class period, alleging that the company misled investors regarding its business operations [1][2]. Group 1: Allegations and Misleading Statements - The lawsuit claims that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements [3]. - It is alleged that the regulatory prospects of the oxylanthanum carbunate (OLC) New Drug Application (NDA) were also overstated [3]. - As a result of these misleading statements, investors reportedly suffered damages when the true details became public [3]. Group 2: Class Action Participation - Shareholders interested in serving as lead plaintiffs must file their motions with the court by October 14, 2025 [4]. - Participation in the class action is not required to be eligible for recovery; shareholders can remain absent class members if they choose [4]. Group 3: Rosen Law Firm Overview - Rosen Law Firm is recognized for its commitment to shareholder rights litigation and has recovered over $1 billion for shareholders since its inception [6].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Unicycive Therapeutics, Inc. regarding a class action lawsuit due to alleged misleading statements and failure to disclose critical information during the specified class period [1][2]. Summary by Relevant Sections Allegations - The complaint alleges that Unicycive Therapeutics overstated its readiness to meet FDA manufacturing compliance requirements, as well as the regulatory prospects of its oxylanthanum carbonate new drug application [1]. - It is claimed that the public statements made by the defendants were materially false and misleading throughout the class period from March 29, 2024, to June 27, 2025 [1]. Class Action Details - Shareholders who purchased shares of UNCY during the class period are encouraged to register for the class action, with a deadline set for October 14, 2025 [2]. - Participants will be enrolled in a portfolio monitoring software to receive updates on the case's progress [2]. Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit, fraud, and illegal business practices, emphasizing the importance of responsible business conduct [3]. - The firm seeks recovery for investors who suffered losses due to misleading statements or omissions that led to artificial inflation of stock prices [3].

Core Points - The Gross Law Firm is notifying shareholders of Unicycive Therapeutics, Inc. regarding a class action lawsuit related to misleading statements made by the company during a specified period [1][3] - The class period for the lawsuit is from March 29, 2024, to June 27, 2025, during which the company allegedly overstated its compliance with FDA manufacturing requirements and the regulatory prospects of its new drug application [3] - Shareholders are encouraged to register for the class action by October 14, 2025, to potentially recover losses incurred due to the alleged misleading statements [4] Company Allegations - The complaint alleges that Unicycive's readiness to meet FDA manufacturing compliance was overstated [3] - It is claimed that the regulatory prospects for the oxylanthanum carbonate new drug application were also overstated [3] - As a result of these issues, the public statements made by the company were materially false and misleading throughout the relevant time [3] Next Steps for Shareholders - Shareholders who purchased shares during the class period can register to be monitored for updates on the case [4] - There is no cost or obligation for shareholders to participate in the class action [4] - The deadline to seek lead plaintiff status is October 14, 2025 [4]

Core Points - A class action securities lawsuit has been filed against Unicycive Therapeutics, Inc. for alleged securities fraud affecting investors between March 29, 2024, and June 27, 2025 [2][3] - The lawsuit claims that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements and the regulatory prospects of its new drug application [3] - Investors who suffered losses during the relevant period have until October 14, 2025, to request to be appointed as lead plaintiff [4] Company Details - Unicycive Therapeutics, Inc. is currently facing legal challenges due to claims of misleading public statements regarding its compliance and regulatory status [3] - The firm Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [5]

Group 1 - The Gross Law Firm has issued a notice to shareholders of Unicycive Therapeutics, Inc. [1]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Unicycive Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's compliance with FDA manufacturing requirements and the regulatory prospects of its New Drug Application (NDA) for OLC [4][6]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Unicycive between March 29, 2024, and June 27, 2025, to discuss their legal rights [1][4]. - There is a deadline of October 14, 2025, for investors to seek the role of lead plaintiff in the federal securities class action against Unicycive [4][9]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [5]. Group 2: Allegations Against Unicycive - The complaint alleges that Unicycive and its executives made false and misleading statements regarding the company's ability to meet FDA manufacturing compliance requirements and the prospects of the OLC NDA [6]. - On June 10, 2025, Unicycive disclosed deficiencies in cGMP compliance at a third-party manufacturing vendor, leading to a stock price drop of $3.68 per share, or 40.89%, closing at $5.32 [7]. - Following a Complete Response Letter from the FDA on June 30, 2025, citing the same cGMP deficiencies, Unicycive's stock fell by $2.03 per share, or 29.85%, closing at $4.77 [8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Unicycive Therapeutics, Inc. due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by October 14, 2025 [1][3]. Group 1: Company Overview - Unicycive Therapeutics, Inc. is under scrutiny for overstating its readiness to meet FDA manufacturing compliance requirements and the regulatory prospects of its OLC NDA [3]. - The company’s stock experienced significant declines following negative FDA communications regarding manufacturing compliance issues [4][5]. Group 2: Legal Proceedings - A federal securities class action has been filed against Unicycive, with the firm encouraging affected investors to discuss their legal rights [1][6]. - The lead plaintiff in the class action will be the investor with the largest financial interest who is also typical of class members [6]. Group 3: Stock Performance - On June 10, 2025, Unicycive's stock fell by $3.68 per share (40.89%) to close at $5.32 after the company disclosed FDA compliance deficiencies [4]. - Following a Complete Response Letter from the FDA on June 30, 2025, the stock dropped by $2.03 per share (29.85%) to close at $4.77 [5].

Core Viewpoint - A class action lawsuit has been filed against Unicycive Therapeutics, Inc. for allegedly misleading investors regarding the readiness of its drug application and compliance with FDA manufacturing requirements [1][2]. Group 1: Allegations and Company Background - Unicycive Therapeutics is a clinical-stage biotechnology company focused on developing therapies for unmet medical needs in the U.S. [1] - The lawsuit claims that Unicycive misrepresented the prospects of its New Drug Application (NDA) for oxylanthanum carbonate (OLC) intended for treating hyperphosphatemia in chronic kidney disease patients on dialysis [2]. - The complaint alleges that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements [2]. Group 2: Recent Developments - On June 10, 2025, Unicycive disclosed that the FDA identified deficiencies in current good manufacturing practice (cGMP) compliance at a third-party manufacturing vendor, which impacted discussions regarding the drug label [3]. - Following this announcement, Unicycive's stock price dropped over 40% [3]. - On June 30, 2025, the FDA issued a Complete Response Letter for the OLC NDA, further citing the cGMP deficiencies, leading to an additional stock price decline of nearly 30%, closing at $4.77 per share [3]. Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against Unicycive and can contact Robbins LLP to serve as lead plaintiff before the October 14, 2025 deadline [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4]. Group 4: Firm Background - Robbins LLP is recognized for its focus on shareholder rights litigation, helping shareholders recover losses and improve corporate governance since 2002 [5].